Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | CPA3 | P15088 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049052 | 0.87 | FOLH1 (0.35) | FFAR1FOLH1CYP1A2 | |
| SCHEMBL7047111 | 0.84 | NAALAD2 (0.39) | MMENAALAD2FFAR1CPA3FOLH1 | |
| SCHEMBL28028444 | 0.81 | FFAR1 (0.50) | NAALAD2FFAR1CPA3FOLH1CYP1A2 | |
| SCHEMBL7049937 | 0.79 | MME (0.44) | MMENAALAD2CPA3CYP1A2 | |
| SCHEMBL7054224 | 0.75 | CPA3 (0.55) | NAALAD2CPA3FOLH1CYP1A2 | |
| SCHEMBL7049053 | 0.75 | CPA3 (0.41) | NAALAD2CPA3FOLH1CYP1A2 | |
| SCHEMBL7052276 | 0.73 | FOLH1 (0.50) | FOLH1CYP1A2 | |
| SCHEMBL7047144 | 0.72 | LMNA (0.34) | FOLH1CYP1A2 | |
| SCHEMBL5051274 | 0.71 | FOLH1 (0.44) | NAALAD2FFAR1CPA3FOLH1CYP1A2 | |
| SCHEMBL28969462 | 0.71 | CYP1A2 (0.54) | NAALAD2FOLH1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| US-6265609-B1 | INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY; IN DRUGS TO TREAT GLUTAMATE ABNORMALITIES; COMPULSIVE DISORDERS AND PROSTATE DISEASES, TO EFFECT NEURONAL ACTIVITIES | GUILFORD PHARMACEUTICALS INC. | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | MME 171/4885NAALAD2 1/4885FFAR1 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.